Genetic Disorder Reference Sheet: ATM Pathogenic Variants

October 18, 2021 by Suzanne M. Mahon DNS, RN, AOCN®, AGN-BC, FAAN

An estimated 1%–2% of adults have one pathogenic ataxia telangiectasia mutated (ATM) gene variant (heterozygous) and are considered (https://www.mdpi.com/1718-7729/25/2/3707) carriers. People who are homozygous (two altered copies) have ataxia-telangiectasia (A-T), a hereditary condition that often appears in childhood and is characterized by progressive neurologic problems that lead to difficulty walking and an increased (https://www.ncbi.nlm.nih.gov/books/NBK26468/) risk for developing various malignancies. Children with A-T may begin staggering and appear unsteady (ataxia) shortly after learning to walk.

The ATM gene is located (https://www.ncbi.nlm.nih.gov/books/NBK26468/) on chromosome 11 and provides (https://www.mdpi.com/2072-6694/12/3/687) instructions for making the ATM protein that helps control the rate at which cells grow and divide. The protein assists cells in recognizing damaged or broken DNA strands and activating enzymes to repair them.

Cancer Risks

Heterozygous germline ATM pathogenic variants are associated (https://cancerpreventionresearch.aacrjournals.org/content/14/4/433) with an increased risk for developing a variety of cancers, including breast, colon, prostate, gastric, pancreatic, melanoma, and ovarian and possibly other cancers. The ATM gene is considered a moderate risk penetrance gene, meaning the risk of developing a malignancy in an individual who carries a pathogenic variant is two to four times that of the general population. The risks vary with the specific variant and are associated with family history. See the sidebar for recommended prevention and screening strategies.

Treatment Implications

Emerging evidence (https://www.mdpi.com/2072-6694/12/3/687) suggests that poly-ADP ribose polymerase (PARP) inhibitors may be an effective treatment for breast, colon, lung, and other cancers in patients with an actionable ATM variant.

People with homozygous pathogenic ATM gene variants are hypersensitive (https://www.ncbi.nlm.nih.gov/books/NBK26468/) to radiation therapy. The evidence with respect to the safety of radiation therapy in heterozygotes is mixed; some data suggest (https://www.tandfonline.com/doi/full/10.1080/09553002.2017.1344363) increased toxicity in carriers, but other studies (https://www.mdpi.com/1718-7729/25/2/3707) have not. The evidence is currently insufficient to make recommendations about radiation therapy in heterozygous carriers.

Nursing Implications

Once a pathogenic germline ATM variant is identified in a family, other family members should be referred to a genetics professional for counseling about testing options. People with a pathogenic ATM variant require ongoing screening to reduce their risk for morbidity and mortality associated with cancer. Because the exact risks are not fully understood, screening recommendations include family medical history as a consideration (see sidebar).

Knowledge of the risks and management of those with a pathogenic ATM variant is continually evolving, so regular consultation with a genetics professional is important to ensure that patients are following current and appropriate recommendations. Nurses can provide patient and family education about how knowledge of an ATM pathogenic variant guides treatment decisions.

Risk, Prevention, and Screening for Heterozygous Pathogenic ATM Variant

Organ	Risk (ATM vs. General)	Prevention	Screening
Breast in assigned female	28%–50% (12%–13%)	Consider risk-reducing mastectomy based on personal and family history of breast cancer	Initiate breast surveillance (i.e., mammography and clinical breast examination) based on family history, typically 5–10 years earlier than the youngest breast cancer family diagnosis but no later than age 40. Educate about symptoms to report promptly. Consider breast magnetic resonance imaging (MRI) alternating every six months with mammography.
Breast in assigned male	2%–3% (< 1%)		Educate about symptoms to report promptly. Receive annual clinical breast examination.
Pancreas	5%–10% (< 1%)		Consider annual surveillance with abdominal MRI, magnetic resonance cholangiopancreatography, or endoscopic ultrasound. Patients with one or more first- or second-degree relatives from the same side of the family as the ATM pathogenic variant may consider research trials. Screening is generally initiated at age 40, factoring for the youngest age of family diagnosis. No specific screening recommendations for patients without a close family history of pancreatic cancer
Prostate	< 30% (11%)		No consensus guidelines outline screening recommendations. Consider family history and prostate cancer surveillance options (e.g., prostate-specific antigen, digital rectal exam).
Ovary	3%–5% (1%)	Insufficient evidence to recommend risk-reducing salpingo-oophorectomy based on ATM pathogenic variant alone. Consider patient and family history of ovarian cancer.	Obtain gynecologic exam every 6–12 months. Consider pelvic ultrasound.
Colorectal	8% (4%)		Begin colonoscopy every five years by age 40. Screen more frequently and earlier depending on personal and family history of polyps and colon cancer.
Gastric	4% (1%)		Obtain esophagogastroduodenoscopy during colonoscopy.
Melanoma	7%–8% (3%–4%)	Avoid artificial ultraviolet light. Use SPF 30 sunscreen, hats, protective clothing, and sunglasses.	Educate about symptoms to report promptly. Conduct a clinical skin exam at least annually.

Note. Based on information from American Cancer Society (https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html), Hall et al. (https://cancerpreventionresearch.aacrjournals.org/content/14/4/433), Jerzak et al. (https://www.mdpi.com/1718-7729/25/2/3707), Jette et al. (https://www.mdpi.com/2072-6694/12/3/687), and National Comprehensive (https://jnccn.org/view/journals/jnccn/18/4/article-p380.xml) Cancer Network (https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf).

Topics: